Navigation Links
Nicotine Replacement Therapy Is Safe, Effective and Can Help Reverse Mental Acuity Deficits in Smokers Who Are Quitting, Including Commercial and Private Pilots
Date:5/22/2008

Commit 4 mg Lozenge helps reverse symptoms associated with nicotine withdrawal including difficulty concentrating, attention deficit, memory

deficit and selective attention deficit

PITTSBURGH, May 22 /PRNewswire-FirstCall/ -- In light of today's announcement by the Federal Aviation Administration (FAA) that it has removed a prescription anti-smoking pill from their approved list of safe medications for pilots and air-traffic controllers, it's important to note this news does not include nicotine replacement therapy (NRT) which is deemed safe and effective. (1) Further, recent research has found the Commit 4 mg lozenge has been clinically proven to help reverse nicotine withdrawal symptoms associated with quitting smoking including the following: difficulty concentrating, attention deficit, short-term memory deficit and selective attention deficit (2) -- some of the issues at the core of today's report.

In 1994, the FAA requested the Centers for Disease Control (CDC) assemble an expert panel to examine the effects of smoking and tobacco addiction and withdrawal on pilot performance and airline safety. As part of the panel's conclusion, they found NRT to be safe, effective treatment option for pilots who smoke. (1) Those recommendations stand to this day.

"Nicotine withdrawal is a serious issue for pilots who are in the process of quitting smoking, and today's news could have a dramatic impact on these individuals," said Jack E. Henningfield, Ph.D., Professor in the Department of Psychiatry and Behavioral Sciences at the Johns Hopkins University School of Medicine, Vice President Research & Health Policy, Pinney Associates, and consultant for GlaxoSmithKline Consumer Healthcare. "What they need to understand is that NRT such as the Commit lozenge is safe for quitters, including pilots who use it while flying, (1) and can help with the serious effects of withdrawal."

Smoking remains one of the leading causes of preventable death and disease and one of the most powerful and important addictions to break and many smokers can't do it alone. Evidence-based treatments, such as NRT offer a better chance of quitting versus cold turkey, where only 3-5 percent of smokers are successful long-term. (3)

Nicotine replacement therapy including the Commit lozenge, Nicorette gum and NicoDerm CQ patch can help relieve withdrawal symptoms and cravings during smoking cessation. More than 110 studies involving approximately 40,000 smokers have demonstrated the safety of NRT even in populations with specific health conditions, such as diabetes, high blood pressure, lung disease, and existing heart disease. (4)

About the Commit Lozenge

Commit is approved by the FDA to help control tough cravings associated with quitting smoking. (5) Commit has a groundbreaking dosage selector based on how soon a smoker smokes his first cigarette in the morning, so he can choose the strength that's right for him. The Commit lozenge helps people stop smoking by providing low, safe doses of NRT to ease withdrawal from cigarettes. Commit comes in different strengths -- 2 mg or 4 mg -- to be used depending on how soon a smoker has his first cigarette in the morning. The 2 mg dosage is for smokers who usually have their first cigarette more than thirty minutes after waking up. The 4 mg dosage is for smokers who usually have their first cigarette within thirty minutes of waking up.

About GlaxoSmithKline Consumer Healthcare

GlaxoSmithKline (GSK) Consumer Healthcare is one of the world's largest over-the-counter consumer healthcare products companies. GSK offers the widest range of proven NRT products available, products which can significantly improve a smoker's chance of quitting successfully and have helped millions of people quit smoking. In addition, GSK offers several resources and support services designed specifically to help smokers and non-smokers understand and address the two components to smoking cessation: nicotine addiction and habit change. Its more than 30 well-known brands include the leading smoking cessation products, Nicorette(R), NicoDerm(R) CQ and Commit(R) as well as many medicine cabinet staples, including Abreva(R), alli(R) Aquafresh(R), Sensodyne(R), Tums(R) and Breathe Right(R), trademarks owned and/or licensed to GlaxoSmithKline Group of Companies.

About GlaxoSmithKline

GlaxoSmithKline is one of the world's leading research-based pharmaceutical and consumer healthcare companies. GlaxoSmithKline is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

(1) Fiore 1994, The effects of smoking and smoking withdrawal on flight

performance.

(2) GSK Data on file, Study S2540345 report Boyle et al 2006.

(3) Fiore MC, Bailey WC, Cohen SJ, et al. Treating Tobacco Use and

Dependence. Clinical Practice Guideline. Rockville, MD:

(4) Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine

replacement therapy for smoking cessation. Cochrane Database of

Systematic Reviews 2008, Issue 1. Art. No.: CD000146. DOI:

10.1002/14651858.CD000146.pub3.

(5) FDA labeling for gum/lozenge/patch. 2005. Labels on boxes of

Nicorette, Commit and NicoDerm CQ

Media Contacts: Samantha Schwarz, GolinHarris

312-622-1124

sschwarz@golinharris.com

Jennifer May, GlaxoSmithKline Consumer Healthcare

412-200-3729

jennifer.l.may@gsk.com


'/>"/>
SOURCE GlaxoSmithKline Consumer Healthcare
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Perrigo Receives FDA Approval to Market Orange, Coated Nicotine Gum
2. DNA (driver of nicotine addiction)
3. American Legacy Foundation Comments on New York State Department of Health Petition to the FDA to Expand Consumer Access to Over the Counter Nicotine Medications
4. Smokers Brain Centers Activate During Nicotine Cravings
5. Study suggests nicotine addiction might be controlled by influencing brain mechanisms
6. Smoking Cessation Rates Double With Intensive Counseling and Free Nicotine Replacement Therapy, Studies of 20,000 Smokers Show
7. Studies of 20,000 smokers show quit rates double with counseling and free nicotine patches
8. Nicotine-Reduced Cigarettes Could Boost Quitting
9. Nicotine addiction slashed in test of new cigarette smoking strategy
10. Nicotine Plus Alcohol May Be Tough to Beat
11. Genes, brain chemistry may dictate nicotine cravings, says CU-Boulder study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 2017 , ... The American Board of Family Medicine's (ABFM) Board of Directors ... Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. Newton will serve in ... retirement at the end of 2018. Upon assuming the role of President and CEO ...
(Date:10/13/2017)... , ... October 13, 2017 ... ... of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ... on guideline updates for the primary prevention of cardiovascular diseases during the ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Many families ... However, many long-term care insurance companies have a waiver for care if the client ... elimination period, when the family pays for care, is often waived, so the benefits ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in agile ... a contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise ... use of Agile methodologies in a consistent and high value manner across CMS ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... LAWRENCE, Mass. , Oct. 4, 2017 /PRNewswire/ ... developer of single-use, self-contained, illuminating medical devices, today ... National Health Surveillance Agency (or Agência Nacional ... ®. The first single-use, cordless surgical retractor with ... ONETRAC provides optimal access, illumination and exposure of ...
(Date:10/2/2017)... Oct. 2, 2017  Eli Lilly and Company (NYSE: ... for the third quarter of 2017 on Tuesday, October ... on that day with the investment community and media ... The conference call will begin at 9 a.m. Eastern ... a live webcast of the conference call through a ...
(Date:10/2/2017)... Halo Labs announces the European launch of their new low volume, ... 2017 in Cambridge, U.K on October 4th. ... samples with unprecedented speed and sensitivity while using far less sample ... ... system ...
Breaking Medicine Technology: